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The target audience for this guideline is primary care physicians. The guideline applies to patients with acute migraine attacks, with or without aura, and patients with migraine who are candidates for preventive drug therapy. Although these guidelines are all based on the articles by Matchar and Ramadan and colleagues, the recommendations may differ because different thresholds of evidence were needed for making a positive recommendation. Table 1 compares the AAFP/ACP-ASIM guideline and the U.S. Headache Consortium Guideline.
Throughout the text, asterisks indicate drugs that are currently not available in the United States.
DIAGNOSIS
Headache has many potential causes. Most headaches are caused by the primary headache disorders, which include migraine, cluster, and tension-type headaches. Secondary headaches, which are those with underlying pathologic causes, are far less common. Migraine is a chronic condition with recurrent acute attacks whose characteristics vary among patients and often among attacks within a single patient. Migraine is a syndrome with a wide variety of neurologic and non-neurologic manifestations. The International Headache Society (6) has developed diagnostic criteria for migraine with and without aura (Appendix Table 1 ). This classification system serves to diagnose headache syndromes, not patients. Thus, one patient could have more than one type of headache disorder. For example, it is not uncommon for migraine patients to also have episodic tension-type headaches.
MANAGEMENT OF ACUTE ATTACKS
Effective long-term management of patients with migraine is challenging because of the complexity of the condition. Experts suggest several goals for successful treatment of acute attacks of migraine. These include treating attacks rapidly and consistently to avoid headache recurrence, to restore the patient's ability to function, and to minimize the use of backup and rescue medications.
Clinicians need to educate people with migraine about their condition and its treatment and encourage them to participate in their own management. The physician must help the patient establish realistic expectations by discussing therapeutic options and their benefits and harms. Patient input can provide the best guide to treatment selection and helps the physician to better understand and accommodate patient treatment goals. Developing an effective acute migraine management strategy can be complex, and an engaged patient is more likely to negotiate this process successfully. Encouraging patients to identify and avoid triggers ( Table 2 ) and to be actively involved in their own management by tracking their own progress may be especially useful.
Once a diagnosis of migraine is established, patients
and their health care providers should decide together how to treat acute attacks and whether the patient is a candidate for preventive medications. A wide range of acute treatments with varying efficacies is currently in use (Appendix Table 2 , available at www.annals.org). A comprehensive review of the scientific literature, especially the data from randomized, controlled trials, provides a list of treatments that have demonstrated efficacy in the management of acute migraine headache. It also provides a clear understanding of the adverse events associated with various agents. The Headache Consortium's review of the evidence on antiemetics, barbiturate hypnotics, ergot alkaloids and derivatives, nonsteroidal anti-inflammatory drugs (NSAIDs), combination analgesics and nonopiate analgesics, opiate analgesics, triptans, and other agents found good evidence of the efficacy of only a few agents in the treatment of acute migraine (3) .
Available Agents

NSAIDs
Their demonstrated efficacy and favorable tolerability make NSAIDs a first-line treatment choice for all migraine attacks, including severe attacks that have responded to NSAIDs in the past. Among the NSAIDs, the most consistent evidence exists for aspirin (8 -10) , ibuprofen (11, 12) , naproxen sodium (13, 14) , tolfenamic acid* (8, 15) , and the combination agent acetaminophen plus aspirin plus caffeine for the acute treatment of migraine (16) . The evidence shows that acetaminophen alone is ineffective (17) .
Serotonin 1B/1D Agonists (Triptans)
There is good evidence for the effectiveness of the oral triptans naratriptan (18, 19) , rizatriptan (20 -23) , sumatriptan (24 -31) , and zolmitriptan (32) (33) (34) . In addition, there is good evidence for the effectiveness of subcutaneous (35) (36) (37) (38) and intranasal (39 -41) sumatriptan, making it an option for patients with nausea and vomiting. Adverse effects of the triptans include chest symptoms, but postmarketing data indicate that true ischemic events are rare. Triptans are contraindicated in patients with risk for heart disease, basilar or hemiplegic migraine, or uncontrolled hypertension. Subcutaneous sumatriptan is associated with a very rapid onset of action, and oral naratriptan is associated with a slower onset of action.
Ergotamines
There is good evidence for the efficacy and safety of intranasal dihydroergotamine (DHE) as monotherapy for acute migraine attacks (42-46). Placebo-controlled studies of intravenous DHE did not clearly establish its efficacy in the acute treatment of migraine (47, 48) . The evidence was inconsistent to support efficacy of ergotamine or ergotamine-caffeine, and the studies documented frequent adverse events.
Opioids
It is well recognized that opiates are good analgesics, but there is good evidence only for the efficacy of butorphanol nasal spray (49, 50) . Although opioids are commonly used, surprisingly few studies of opioid use in headache pain document whether overuse and the development of dependence are as frequent as clinically perceived. Until further data are available, these drugs may be better reserved for use when other medications cannot be used, when sedation effects are not a concern, or the risk for abuse has been addressed.
Other Agents
Fair evidence suggests that the antiemetic metoclopramide, given intravenously, may be an appropriate choice as monotherapy for acute attacks (51) (52) (53) , particularly in patients with nausea and vomiting when the sedating side effect may also be useful. Isometheptene and isometheptene combinations obtained only borderline significance in relieving headache pain (17, 54, 55) . Other agents used in practice, such as intravenous corticosteroids and intranasal lidocaine, are not effective.
Choice of Treatment
Since patient responses to these therapies are not always predictable, individualized management is important. The choice of treatment should be based on, among other characteristics, the frequency and severity of attacks; the presence and degree of temporary disability; and the profile of associated symptoms, such as nausea and vomiting. The patient's history of, response to, and tolerance for specific medications must also be considered. Coexisting conditions (such as heart disease, pregnancy, and uncontrolled hypertension) may limit treatment choices.
No studies document the effectiveness of specific treatment schedules, but experts suggest that acute therapy should be limited to no more than two times per week to guard against medication-overuse headache (or druginduced headache). Medication-overuse headache is thought to result from frequent use of acute medication and has a pattern of increasing headache frequency, often resulting in daily headaches. In patients with suspected medication overuse or patients at risk for medication overuse, preventive migraine therapy should be considered.
Although some use the term rebound headache interchangeably with the term medication-overuse headache, rebound headache is a distinct entity. Rebound headache is associated with withdrawal of analgesics or abortive migraine medication. There is no uniform agreement about which agents can cause rebound headache, although ergotamine (not DHE); opiates; triptans; and simple and mixed analgesics containing butalbital, caffeine, or isometheptene Select a non-oral route of administration for patients whose migraines present early with nausea or vomiting as a significant component of the symptom complex. Treat nausea and vomiting with an antiemetic.
Consider a self-administered rescue medication for patients with severe migraine that does not respond well to or fails other treatments ‡.
Guard against medication-overuse headache.
Educate patients with migraine about their condition and its treatment, and encourage them to participate in their own management
Educate patients with migraine about their condition and its treatment, and encourage them to participate in their own management Preventive Medication use Initiate treatment with lowest effective dose Give each treatment an adequate trial Avoid interfering medications Use a long-acting formulation to improve adherence
Patients with migraine should be evaluated for use of preventive therapy. Generally accepted indications for migraine prevention include 1) two or more attacks per month that produce disability that lasts 3 or more days per month; 2) contraindication to, or failure of, acute treatments; 3) use of abortive medication more than twice per week; or 4) the presence of uncommon migraine conditions, including hemiplegic migraine, migraine with prolonged aura, or migrainous infarction. Another clinical consideration is the use of a selfadministered rescue medication for patients with severe migraine attack that is not responding to (or failing) other treatments. A rescue medication is an agent such as an opioid or a butalbital-containing compound that the patient can use at home when other treatments have failed. Although rescue medications often do not completely eliminate pain and allow patients to return to normal activities, they permit the patient to achieve relief without the discomfort and expense of a visit to the physician's office or emergency department. A cooperative arrangement between provider and patient may extend to the use of rescue medication in appropriate situations.
Summary of Treatment of Acute Migraine
A body of evidence now points to effective first-and second-line agents for acute treatment of migraine. Beyond the choice of agent lies the choice of management strategy. Recently, interest and research in step care versus stratified care have increased.
Step care refers to the initial use of safe, effective, and inexpensive medications as first-line agents in acute attacks of any severity. If the initial agent fails, a second-line, more expensive, migraine-specific medication is then used. The stratified care model initially stratifies migraine attacks by severity, advocating migrainespecific agents for moderate to severe attacks, regardless of previous response to or an unknown response to other agents. Which approach is more effective is still an open question (56) .
MANAGEMENT OF MIGRAINE WITH PREVENTIVE THERAPY
Once patients and their health care providers decide how to treat acute attacks, use of preventive medications should be considered. Generally accepted indications for migraine prevention include 1) two or more attacks per month that produce disability lasting 3 or more days per month; 2) contraindication to, or failure of, acute treatments; 3) the use of abortive medication more than twice per week; and 4) the presence of uncommon migraine conditions, including hemiplegic migraine, migraine with prolonged aura, or migrainous infarction. Other factors to consider are adverse events with acute therapies, patient preference, and the cost of both acute and preventive therapies. (The U.S. Headache Consortium also produced a document on behavioral and other nonpharmacologic therapies for headache prevention, which can be found at www.aan.com/professionals/practice/guidelines.cfm.)
A wide range of preventive treatments with varying efficacies is currently in use (Appendix Table 3 , available at www.annals.org). A comprehensive review of the scientific literature, especially the data from randomized, controlled trials, provides a list of treatments that have demonstrated efficacy in the prevention of migraine headache. It also provides a clear understanding of the adverse events associated with various agents. The Headache Consortium's review of the evidence on ␣ 2 -agonists, anticonvulsants, antidepressants, ␤-blockers, calcium-channel blockers, NSAIDs, serotonergic agents (ergot derivatives, methysergide, and others), hormone therapy, feverfew, magnesium, Encourage patients to be actively involved in their own management by tracking their own progress through daily flow sheets, for example. Diaries should measure attack frequency, severity, duration, disability, response to type of treatment, and adverse effects of medication.
Comorbid conditions
Once a coexisting condition is identified, select a pharmacologic agent that will treat both disorders Establish that the coexisting condition is not a contraindication to the selected migraine therapies and that the therapy will not exacerbate the migraine * Consortium recommendations are based on references 3 and 4. The ACP-ASIM historically has not used a grading system for guideline recommendations because its development process mandates the use of only high-quality evidence (that is, randomized, controlled trials or "A"-level evidence) as a basis for recommendations. AAFP ϭ American Academy of Family Physicians; ACP-ASIM ϭ American College of Physicians-American Society of Internal Medicine; DHE ϭ dihydroergotamine; IM ϭ intramuscular; IN ϭ intranasal; IV ϭ intravenous; NSAID ϭ nonsteroidal anti-inflammatory drug; SC ϭ subcutaneous. † Currently not available in the United States. ‡ Rescue medication is an agent (e.g., an opioid) that the patient can use at home when other treatments have failed.
Clinical Guidelines
Management and Prevention of Migraine www.annals.organd riboflavin found that there was good evidence of the efficacy of only a few agents in migraine prevention. A summary of these results follows.
Available Agents
␤-Blockers
Evidence consistently showed the efficacy of propranolol, 80 to 240 mg/d (57) (58) (59) (60) (61) (62) (63) , and timolol, 20 to 30 mg/d (63) (64) (65) , for the prevention of migraine. One trial comparing propranolol and amitriptyline suggested that propranolol is more efficacious in patients with migraine alone; amitriptyline was superior for patients with mixed migraine and tension-type headache (66) . There is limited evidence of a moderate effect for atenolol (67, 68) , metoprolol (69 -71), and nadolol (72) (73) (74) . ␤-Blockers with intrinsic sympathomimetic activity (acebutolol, alprenolol, oxprenolol, pindolol) seem to be ineffective for the prevention of migraine. Adverse effects reported most commonly with ␤-blockers were fatigue, depression, nausea, dizziness, and insomnia. These symptoms appear to be fairly well tolerated and seldom caused premature withdrawal from trials.
Antidepressants
Amitriptyline has been more frequently studied than the other antidepressants and is the only one with consistent support for efficacy in migraine prevention (75) (76) (77) . The dosages that were most efficacious in the clinical trials ranged from 30 to 150 mg/d. Drowsiness, weight gain, and anticholinergic symptoms were frequently reported with the tricyclic antidepressants studied, including amitriptyline. There is no evidence for the use of nortriptyline, protriptyline, doxepin, clomipramine, or imipramine. There is limited evidence of a modest effect for fluoxetine at dosages ranging from 20 mg every other day to 40 mg per day (78, 79) . There is no evidence from controlled trials for the use of fluvoxamine, paroxetine, sertraline, phenelzine, bupropion, mirtazapine, trazodone, or venlafaxine.
Anticonvulsants
For the anticonvulsants, there is good evidence for the efficacy of divalproex sodium (80 -82) and sodium valproate (83, 84) . Adverse events with these therapies are not uncommon and include weight gain, hair loss, tremor, and teratogenic potential, such as neural tube defects. These agents may be especially useful in patients with prolonged or atypical migraine aura. Carbamazepine and vigabatrin* have been shown to be ineffective, and there is limited evidence for moderate efficacy of gabapentin (85) .
NSAIDs
A meta-analysis (4) of five of seven placebo-controlled trials of naproxen or naproxen sodium showed a modest effect on headache prevention (62, 86 -92) . Similar trends were observed in single placebo-controlled trials of flurbiprofen, indobufen*, ketoprofen, lornoxicam*, and mefenamic acid and in two trials of tolfenamic acid*. Placebocontrolled trials of aspirin, aspirin plus dipyridamole, fenoprofen, and indomethacin were inconclusive. There is no evidence for the use of ibuprofen or nabumetone in the prevention of migraine.
Side effect rates for naproxen were not significantly higher than those seen with placebo. The most commonly reported adverse events with all NSAIDs were gastrointestinal symptoms, including nausea, vomiting, gastritis, and blood in the stool. In the trials reviewed, such symptoms were reported by 3% to 45% of participants (86).
Serotonergic Agents
Of these agents, time-released DHE* had the strongest support, with consistently positive findings in four placebo-controlled trials (93) (94) (95) (96) . Evidence is insufficient for the efficacy of ergotamine or ergotamine plus caffeine plus butalbital plus belladonna alkaloids or methylergonovine for migraine prevention. Limited information was reported on adverse events associated with these agents. The most commonly reported events for all the ergot alkaloids were gastrointestinal symptoms.
There is strong evidence for the efficacy of methysergide (97-100), a semisynthetic ergot alkaloid. However, there are reports of retroperitoneal and retropleural fibrosis associated with long-term, mostly uninterrupted administration. The manufacturer suggests that methysergide therapy be discontinued for 3 to 4 weeks after each 6-month course of treatment. Other adverse events most commonly reported included gastrointestinal symptoms and leg symptoms (restlessness or pain).
Other serotonergic agents that have been evaluated for the prevention of migraine include pizotifen*, lisuride*, oxitriptan*, iprazochrome*, and tropisetron*. Only Clinical Guidelines Management and Prevention of Migraine lisuride (101-104) and pizotifen (87, 99, (105) (106) (107) (108) (109) (110) have consistent evidence that supports their efficacy in the prevention of migraine. Published data on adverse events associated with lisuride are limited, and pizotifen is often associated with weight gain and drowsiness.
Calcium-Channel Blockers
The evidence for nifedipine, nimodipine, cyclandelate*, and verapamil is poor quality and difficult to interpret, suggesting only a modest effect (see reference 4 for study references). There is no evidence for the use of diltiazem in the prevention of migraine. Symptoms reported with these agents included dizziness, edema, flushing, and constipation.
Flunarizine*, 10 mg/d, has proven efficacy in the prevention of migraine and is commonly used in countries where it is available (111) (112) (113) (114) (115) . Adverse events reported with flunarizine include sedation, weight gain, and abdominal pain. Depression and extrapyramidal symptoms can be observed, particularly in elderly persons.
There is good evidence for the lack of efficacy of the ␣ 2 -agonist clonidine in the prevention of migraine (116 -120) . Limited evidence shows moderate efficacy of guanfacine (121).
Hormone Therapy, Feverfew, Magnesium, and Riboflavin
There is fair evidence for modest efficacy of these agents in certain circumstances, but more trials need to be done. Most of the existing trials had small sample sizes, had self-referred or special patient samples, or had other methodologic flaws (see reference 4 for more details and references).
Summary of Preventive Therapy
To alleviate the suffering of many patients with migraine, clinicians need to be aware of the commonly accepted indications for preventive therapy and initiate effective therapy in those patients. Although many agents are available for the preventive treatment of migraine, only a few have proven efficacy. Once an agent has been chosen, clinicians should initiate therapy with a low dose and titrate the dose slowly up until clinical benefits are achieved in the absence of adverse events or until limited by adverse events. Because a clinical benefit may take as long as 2 to 3 months to manifest, each treatment should be given an adequate trial. Once preventive treatment is under way, interfering medications, such as overused acute medications such as ergotamine, should be avoided. After a period of stability, clinicians should consider tapering or discontinuing treatment. Patient and clinician need to engage in an ongoing dialogue in which patient expectations and goals for therapy are taken into account when agents are chosen, titrated, or discontinued.
RECOMMENDATIONS
Recommendation 1: For most migraine sufferers, nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapy.
To date, the most consistent evidence exists for aspirin, ibuprofen, naproxen sodium, tolfenamic acid*, and the combination agent acetaminophen plus aspirin plus caffeine. There is no evidence for the use of acetaminophen alone.
Recommendation 2: In patients whose migraine attack has not responded to NSAIDs, use migraine-specific agents (triptans, DHE).
There is good evidence for the following triptans: oral naratriptan, rizatriptan, and zolmitriptan; oral and subcu- History and physical and neurologic examination do not suggest one of the disorders causing secondary headaches. History and/or physical and/or neurologic examinations suggest such a disorder, but it is ruled out by appropriate investigations. One of such disorders is present, but migraine attacks do not occur for the first time in close temporal relation to the disorder. Migraine with aura A. At least two attacks fulfilling criterion B B. At least three of the following four characteristics One or more fully reversible aura symptoms indicating focal cerebral cortical and/or brain stem dysfunction At least one aura symptom developing gradually over more than 4 minutes, or two or more symptoms occurring in succession No aura symptom lasting more than 60 minutes; if more than one aura symptom is present, accepted duration is proportionally increased. Headache following aura with a free interval of less than 60 minutes (It may also begin before or simultaneously with the aura.) C. At least one of the following:
History and physical and neurologic examinations do not suggest one of the following disorders: Headache associated with head trauma Headache associated with vascular disorders Headache associated with nonvascular intracranial disorder Headache associated with substances or their withdrawal Headache associated with noncephalic disorder Headache associated with metabolic disorder Headache or facial pain associated with disorders of the cranium; neck; or ear, nose, and throat Cranial neuralgias History and/or physical and/or neurologic examinations suggest such a disorder, but it is ruled out by appropriate investigations. Such a disorder is present, but migraine attacks do not occur for the first time in close temporal relation to the disorder.
* For migraine without aura, headaches must meet criterion A; those five attacks must fulfill criteria B through D and must fulfill at least one of the criteria under E. For migraine with aura, headaches must meet criterion A; those two attacks must fulfill criteria B and at least one of those listed under C. Adapted from reference 6. Evidence is limited, but in some patients, concomitant treatment with an antiemetic and an oral migraine medication may be appropriate. Antiemetics should not be restricted to patients who are vomiting or likely to vomit. Nausea itself is one of the most aversive and disabling symptoms of a migraine attack and should be treated appropriately.
Clinical Guidelines
Recommendation 4: Migraine sufferers should be evaluated for use of preventive therapy.
Generally accepted indications for migraine prevention include 1) two or more attacks per month that produce disability lasting 3 or more days per month; 2) contraindication to, or failure of, acute treatments; 3) use of abortive medication more than twice per week; or 4) the presence of uncommon migraine conditions, including hemiplegic migraine, migraine with prolonged aura, or migrainous infarction. Medications with proven efficacy but limited published data on adverse events or frequent or severe adverse events include flunarizine*, lisuride*, pizotifen*, timereleased DHE*, and methysergide.
Recommendation 6: Educate migraine sufferers about the control of acute attacks and preventive therapy and engage them in the formulation of a management plan. Therapy should be reevaluated on a regular basis.
There is strong consensus about the need for educating people with migraine. The physician must help the patient establish realistic expectations by discussing therapeutic options and their benefits and harms, such as medicationoveruse headache. Encouraging patients to be actively involved in their own management by tracking their own progress through daily flow sheets, for example, may be especially useful. Diaries should measure attack frequency, severity, and duration; resulting disability; response to type of treatment; and adverse effects of medication. Patient input can provide the best guide to treatment selection. Note: Clinical practice guidelines are "guides" only and may not apply to all patients and all clinical situations. Thus, they are not intended to override clinicians' judgment. All ACP-ASIM clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication or once an update has been issued. 
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